statistiche ricercatore

Continente	#
NA - Nord America	713
AS - Asia	335
EU - Europa	190
SA - Sud America	49
AF - Africa	9
Continente sconosciuto - Info sul continente non disponibili	2
OC - Oceania	2
Totale	1.300

Nazione	#
US - Stati Uniti d'America	703
SG - Singapore	136
HK - Hong Kong	70
CN - Cina	65
SE - Svezia	45
BR - Brasile	37
GB - Regno Unito	36
VN - Vietnam	35
FI - Finlandia	23
RU - Federazione Russa	22
DE - Germania	21
BG - Bulgaria	10
AR - Argentina	8
FR - Francia	8
CA - Canada	7
ID - Indonesia	7
IT - Italia	7
IN - India	6
NL - Olanda	6
TR - Turchia	4
ZA - Sudafrica	4
AE - Emirati Arabi Uniti	3
SA - Arabia Saudita	3
UA - Ucraina	3
A2 - ???statistics.table.value.countryCode.A2???	2
AU - Australia	2
BD - Bangladesh	2
IE - Irlanda	2
JP - Giappone	2
MA - Marocco	2
MX - Messico	2
PT - Portogallo	2
AT - Austria	1
CL - Cile	1
CO - Colombia	1
EC - Ecuador	1
EG - Egitto	1
ES - Italia	1
IQ - Iraq	1
JM - Giamaica	1
KE - Kenya	1
MD - Moldavia	1
MK - Macedonia	1
NO - Norvegia	1
PH - Filippine	1
PY - Paraguay	1
TN - Tunisia	1
Totale	1.300

Nome	#
Clinical and serological profile of primary biliary cirrhosis in men	160
Clinical Impact and behaviour of serum autoantibodies in adult liver transplantation	143
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis	141
Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis	140
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants	129
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways	124
De novo autoimmune hepatitis in liver transplant: State-of-the-art review	123
Pathway-based analysis of primary biliary cirrhosis genome-wide association studies	122
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score	121
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program	113
Totale	1.316

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	90	0	0	0	0	0	0	0	0	51	0	38	1
2021/2022	169	29	8	10	8	0	4	4	14	23	22	24	23
2022/2023	215	32	24	19	23	22	40	1	20	20	1	8	5
2023/2024	109	1	10	5	22	27	1	20	7	2	2	0	12
2024/2025	369	7	2	4	27	81	60	13	26	61	9	21	58
2025/2026	364	51	17	36	64	128	66	2	0	0	0	0	0
Totale													1.316